Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
February 22 2017 - 4:36PM
Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated
to identifying, developing and commercializing innovative,
differentiated therapies to improve the lives of patients with
dermatologic diseases, today announced that it will report fourth
quarter and full year 2016 financial results after the close of
U.S. financial markets on February 28, 2017. Dermira’s management
will host a webcast and conference call at 4:30 p.m. ET/1:30 p.m.
PT that day to discuss the financial results and provide a
corporate update and financial guidance for 2017.
A live webcast and archive of the call will be available online
from the investor relations section of the company website at
www.dermira.com. The live call also may be accessed by dialing
877-359-9508 for domestic callers or 224-357-2393 for international
callers and using the conference code: 77463468. A telephone replay
of the call will be available by dialing 855-859-2056 for domestic
callers or 404-537-3406 for international callers and entering the
conference code: 77463468.
About Dermira
Dermira is a biopharmaceutical company dedicated to identifying,
developing and commercializing innovative, differentiated therapies
to improve the lives of patients with dermatologic diseases.
Dermira's portfolio includes three Phase 3 product candidates that
target significant unmet needs and market opportunities: CIMZIA®
(certolizumab pegol), in development in collaboration with UCB
Pharma S.A. for the treatment of moderate-to-severe chronic plaque
psoriasis; DRM04, in development for the treatment of primary
axillary hyperhidrosis (excessive underarm sweating); and
olumacostat glasaretil, in development for the treatment of acne
vulgaris. Dermira is headquartered in Menlo Park, California. For
more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com) and LinkedIn
page (https://www.linkedin.com/company/dermira-inc-) as channels of
distribution of information about its company, product candidates,
planned financial and other announcements, attendance at upcoming
investor and industry conferences and other matters. Such
information may be deemed material information and Dermira may use
these channels to comply with its disclosure obligations under
Regulation FD. Therefore, investors should monitor Dermira’s
website and LinkedIn page in addition to following its SEC filings,
press releases, public conference calls and webcasts.
Contacts:
Media:
Erica Jefferson
Senior Director, Head of Corporate Communications
650-421-7216
erica.jefferson@dermira.com
Investors:
Andrew Guggenhime
Chief Operating Officer and Chief Financial Officer
650.421.7200
investors@dermira.com
Robert H. Uhl
Managing Director
Westwicke Partners
858.356.5932
robert.uhl@westwicke.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Apr 2023 to Apr 2024